ArticleCancer cytopathology2019
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology.
Article in Cancer cytopathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Integration of AI-driven ultrasound and molecular testing to improve diagnosis of indeterminate thyroid nodules.Frontiers in endocrinology · 2026Pooled it
- Article
- Article
- Artificial intelligence in thyroid nodules and cancer: clinical validation and real-world performance.Endocrine connections · 2026Article
- Genome near-haploidization in CDC73-wildtype parathyroid tumors.Scientific reports · 2026Article
- Assessing the accuracy of thyroid nodule risk-stratification tools in Hispanic and non-Hispanic patients.Journal of the Endocrine Society · 2026Article
- Impact of Co-Mutations and Genetic Variations on Malignancy Risk in RAS-Positive Indeterminate Thyroid Nodules: an Institutional Experience.Endocrine pathology · 2026Article
- A malignancy risk prediction model for Bethesda category III thyroid nodules based on serological indicators, C-TIRADS, and BRAF V600E testing.Frontiers in endocrinology · 2026Article
- External validation of a microRNA thyroid classifier: a real-world prospective study.European thyroid journal · 2025Observational
- HighCancers · 2025Article
- Performance of the AmpliSeq NGS panel in thyroid nodules with indeterminate cytology.European thyroid journal · 2025Article
- Article
- Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing.Current oncology (Toronto, Ont.) · 2024Article
- Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- Article
- Editorial: Molecular characterization of thyroid lesions in the era of "next generation" techniques: volume II.Frontiers in endocrinology · 2024Article
- Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2023Article
- Coexisting Molecular Alterations Increase the Risk of Malignancy in Thyroid Nodules with Copy Number Alterations.Cancers · 2022Article
- Clinicopathologic Characteristics of Pediatric Follicular Variant of Papillary Thyroid Carcinoma Subtypes: A Retrospective Cohort Study.Thyroid : official journal of the American Thyroid Association · 2022Article
- Do ACR TI-RADS scores demonstrate unique thyroid molecular profiles?Ultrasonography (Seoul, Korea) · 2022Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.